Aldeyra Therapeutics, Inc. (ALDX) Form 10-Q Quarterly Reports
Aldeyra Therapeutics, Inc. (ALDX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ALDX
CIK: 1341235
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
BDO USA, P.C.
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerDouglas Gustin
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-29 | 2026-09-29 | 8-K | 0001193125-26-405954 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-12 | — | SCHEDULE 13G Filing | 0001167557-26-000132 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001341235-26-000010 | View SEC Doc Filr Page |
| 8-K | 2026-07-30 | 2026-07-28 | 8-K | 0001193125-26-326337 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-27 | — | SCHEDULE 13G/A Filing | 0002012383-26-002166 | View SEC Doc Filr Page |
| 8-K | 2026-07-15 | 2026-07-14 | 8-K | 0001193125-26-304880 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267634 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267629 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267623 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267611 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267605 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267600 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | 4 | 0001193125-26-267587 | View SEC Doc Filr Page |
| 3 | 2026-06-11 | 2026-06-09 | 3 | 0001193125-26-267553 | View SEC Doc Filr Page |
| 8-K | 2026-06-10 | 2026-06-09 | 8-K | 0001193125-26-264514 | View SEC Doc Filr Page |
| 4 | 2026-06-05 | 2026-06-03 | 4 | 0001193125-26-259637 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001193125-26-226558 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | 10-Q | 0001341235-26-000006 | View SEC Doc Filr Page |
| 8-K | 2026-05-01 | 2026-05-01 | 8-K | 0001193125-26-199157 | View SEC Doc Filr Page |
| ARS | 2026-04-27 | 2025-12-31 | ARS | 0001193125-26-182133 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-27 | — | DEFA14A | 0001193125-26-182118 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-27 | 2025-06-10 | DEF 14A | 0001193125-26-182099 | View SEC Doc Filr Page |
| 8-K | 2026-04-20 | 2026-04-20 | 8-K | 0001193125-26-164198 | View SEC Doc Filr Page |
| 8-K | 2026-04-01 | 2026-04-01 | 8-K | 0001193125-26-137984 | View SEC Doc Filr Page |
| 4 | 2026-03-31 | 2026-03-27 | 4 | 0001193125-26-134631 | View SEC Doc Filr Page |